

September 11, 2025

To,

National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 NSE Symbol: SUPRIYA

Dear Sir/Madam,

<u>Subject: Clarification for Financial results - SUPRIYA</u>

Ref: Regarding Segment details not submitted in Quick Results.

With reference to your email communication dated September 11, 2025, in connection with the absence of segment details in the quick results submitted by the Company on August 13, 2025, we wish to submit the following clarification:

The Company operates in a single business segment, namely Pharmaceuticals. The omission of segment information in the said submission was due to a typographical error, which occurred inadvertently.

We express our sincere regret for the inadvertent error and respectfully request that this explanation be taken on record.

We reaffirm our commitment to full compliance with the SEBI (LODR) Regulations, 2015. The Company has a track record of timely and accurate disclosures and remains dedicated to upholding these practices in all future filings.

Thank you for your kind attention to this matter.

Yours faithfully
For **Supriya Lifescience Limited**

Prachi Sathe Company Secretary & Compliance Officer

Corporate office

: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.

Tel: +91 22 40332727 / 66942507 Fax: +91 22 26860011 GSTIN: 27AALCS8686A1ZX

CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.— Khed, Dist.— Ratnagiri, Pin: 415 722, Maharashtra, India. Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com